12 juni 2008: Bron ASCO 2008:

Een prospectieve studie uitgevoerd in het hyperthermiecentrum van Bochum in de periode 2000 tot 2007 toont aan dat alleen hyperthermie uitgevoerd met apparatuur met electromagnetische velden (ook bv. hyperthermiecentrum Frankfurt en het Medisch Centrum Keulen werken met deze techniek) zorgt voor significant langere mediane overleving en significant betere kwaliteit van leven. Zelfs genazen een aantal patienten van een inoperabel recidief vertelden de onderzoekers aan een arts die hun kliniek recent bezocht en ons daarover gisteren inlichtte.

U kunt op de website van het SNFK  in het voorlichtingsfilmpje over dendritische celtherapie en over behandelingen in het buitenland zien bij een paar patienten hoe deze apparatuur werkt..  Wij kennen persoonlijk een aantal patienten die met hulp van hyperthermie, al of niet in combinatie met dendritische celtherapie inmiddels minimaal enkele jaren klinisch kankervrij zijn ondanks de prognose van beperkte levensduur door inoperabele en hooggradige conditie van de Glioblastomen (recidief en graad IV). Zie onder veelgestelde vragen waar u in Europa dendritische celtherapie kunt krijgen in combinatie met hyperthermie. 

Onderstaand abstract werd gepresenteerd op ASCO 2008.

Prospective phase II trial for recurrent high-grade gliomas with capacitive coupled low radiofrequency (LRF) hyperthermia.

Abstract No:

2047

Citation:

J Clin Oncol 26: 2008 (May 20 suppl; abstr 2047)

Author(s):

E. D. Hager, H. Sahinbas, D. H. Groenemeyer, F. Migeod

Abstract:

Background: In spite of many new approaches the treatment of malignant gliomas is still disappointing. Concomitant radiotherapy with temozolomide could improve in a RCT median survival of pts with glioblastoma multiforme from 12.1 to 14.6 months (EORTC 26981-22981; NCIC,3; ASCO 2004). About 20% of pts with gliomas benefit from therapy depending on genomic mutations. Deep hyperthermia with low radiofrequency capacitive coupled electrodes (LRF-DHT) at 13.56 MHz is feasible in treating pts with brain tumors (Hager ED et al., ASCO 2003,#470). 4/5 of the effective LRF-energy can induce selectively apoptosis in cancer cells instead of heat. Heat alone would be contraindicated for the treatment of tumors in the brain. Therefore, electro-hyperthermia (EHT) is also referred to this technique. Methods: N=179 pts with highly- malignant gliomas (WHO grade III/IV at recurrence or progression) where treated with LRF-DHT after recurrence and/or progression after first-line therapy of the disease after surgery, radiotherapy and/or chemotherapy. N= 53 pts in the astrocytoma WHO grade III group and N=126 pts in the WHO grade IV group (glioblastoma multiforme), KI >50%, where analyzed in an intention-to-treat observational study. Enrollment time was from 02/2000 to 04/2007. Results: Complete data where collected from all pts and considered for evaluation if at least 1 cycle of LRF-DHT could be performed. The median overall survival times (MST) are listed in table 1. Longstanding complete and partial remissions could be achieved after recurrence in both groups. Conclusions: LRF-DHT is feasible in treating pts with highly malignant gliomas without any severe side effects. Hyperthermia with capacitive coupled electrodes may increase overall median survival time (MST) by about 6 months after recurrence and/or progression after first-line therapy. Quality of life and survival could be improved by this method. Further trials are urgently warranted.

 

 

MST from	Grade III; N = 53 pts months±se [95%CI]	Grade IV; N = 126 pts months±se [95%CI]
1st Diagnosis of Disease	37.0±3.7 [29.8; 44.2]	19.0±1.6 [15.9; 22.1]
1st LRF-Hyperthermia	10.0±1.9 [6.3; 13.7]	7.0±0.8 [5.4; 8.6]
Censored N (%)	14 (26.4%)	25 (19.8%)

 

Abstract Disclosures